Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Search

Astellas Pharma Inc.

US
  • About
    • U.S. Products
      • Medical Safety
        • Safety Data Sheets (v 3.0)
    • Philosophy
      • Charter of Corporate Conduct
    • U.S. Corporate Profile
      • Locations
    • Group Code of Conduct
    • U.S. Leadership
      • Percival Barretto-Ko
      • Joe Devaney
      • Shontelle Dodson
      • Lynn Fenicchia
      • Moyra Knight
      • Mark Reisenauer
      • Steve Sabus
    • Regulations
      • State Regulations
        • California Declaration of Comprehensive Compliance Program
        • Vermont’s Pharmaceutical Marketer Price Disclosure
        • Wholesale Acquisition Cost Information for Colorado Prescribers
      • Consumer Product Safety Commission Regulations
    • Company Facts
      • Astellas Fact Sheet
      • Annual Report
    • Policies & Position Statements
    • Contact Us
    • Procurement
      • Procurement News
      • Prospective Suppliers
      • Existing Suppliers
      • Contact & Resources
      • Authorized Distributors of Records
      • PO terms and conditions
    • Vision & Strategy
    • Governance
    • Political Contributions
    • Ethics & Compliance
    Recommended
    U.S. Corporate Profile

    Learn more about Astellas U.S.

    Read More
  • Innovation
    • Partnering
      • Track Record
      • Areas of Interest
      • Partnering Inquiry
    • R&D
      • Approach
      • Clinical Trials
      • Ethics & Principles
      • Pipeline
    Recommended
    Clinical Trials

    This website provides access to information from Astellas sponsored clinical trials and the purpose is not to promote or advertise any...

    Read More
  • Corporate Responsibility
    • COVID-19 Community Response
    • Commitment To Transparency
      • U.S. Sunshine Act Overview
    • Changing Tomorrow Day
    • Annual Report 2019
    • Corporate Grants
    • Access Accelerated
    • Employee Impact
    • Patient Advocacy
    • Awards & Recognition
    Recommended
    Annual Report 2019

    Steady results as projected for the first year of Strategic Plan 2018.

    Read More
  • News
    • News Releases
      • Stories
      • Corporate
      • Corporate Awards
      • Corporate Social Responsibility
      • Our People
      • Therapeutic Area News
    • The Astellas Way Blog
    • Feature Stories
    • Video Gallery
    • Statements
    • Media Inquiries
    Recommended
    Feature Stories

    Feature Stories showcase the people and programs that bring to life the Astellas Way values and culture.

    Read More

Stakeholders menu

  • COVID-19 Response
  • Patients & Caregivers
    • Support for Patients
      • Astellas Pharma Support Solutions
    • Issues that Matter to You
  • Careers
  • Partnering

Common header menu

  • IMPORTANT NOTICE
  • WORLDWIDE
  • US
  • WORLDWIDE - US
Important Notice

This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

Our Use of Cookies

The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. By using this site, you accept our use of cookies as described in our privacy policy. Please read our privacy policy for more information on the cookies we use, the processing of your personal data and how to delete or block the use of cookies.

Accept and Close
logo
You are now leaving www.astellas.com/us. The website you are linking to is neither owned nor controlled by Astellas.
Astellas is not responsible for the content or services on this site.
Cancel Click here to leave this site.
Previous Pause Next
ASTELLAS AT ASCO GU 2021 ASTELLAS AT ASCO GU 2021

Follow along as we share updates from the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium

Read More
ASTELLAS EXPANDS TOP LEADERSHIP WITH CHIEF BUSINESS OFFICER, CHIEF SCIENTIFIC OFFICER ASTELLAS EXPANDS TOP LEADERSHIP WITH CHIEF BUSINESS OFFICER, CHIEF SCIENTIFIC OFFICER

Successors named to lead US business and Regenerative Medicine Institute

Read More
ASTELLAS ACHIEVES 100% SCORE ON CORPORATE EQUALITY INDEX FOR SEVENTH CONSECUTIVE YEAR ASTELLAS ACHIEVES 100% SCORE ON CORPORATE EQUALITY INDEX FOR SEVENTH CONSECUTIVE YEAR

Astellas received the designation as a Best Place to Work for LGBTQ Equality

Read More
GIVING BACK IS CORE TO OUR CULTURE GIVING BACK IS CORE TO OUR CULTURE

Committing for change through employee volunteerism

Read More
PERCIVAL BARRETTO-KO SPEAKS AT BIOPHARMA CONGRESS PERCIVAL BARRETTO-KO SPEAKS AT BIOPHARMA CONGRESS

Running a biopharma company during a pandemic

Read More
ASTELLAS IS COMMITTED TO COMMUNITY SUPPORT ASTELLAS IS COMMITTED TO COMMUNITY SUPPORT

We are dedicated to supporting local and global communities as part of our COVID-19 response

Read More
revised newest covid UPDATES AND INFORMATION

Find out how we're responding to our patients, our employees and our community

Read More
1
2
3
4
5
6
7

News

  • Latest
Global
News / Media
Jan 13, 2021
Astellas Announces a Research Collaboration with Actinium for Molecular Targeted Radiotherapy
Read More
Global
News / Media
Dec 25, 2020
Hold lifted by FDA on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy (XLMTM)
Read More
Global
News / Media
Dec 07, 2020
KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus
Read More
U.S.A.
News / Therapeutic Area News
Jan 06, 2021
FDA Accepts for Priority Review the New Drug Application for mirabegron for Oral Suspension and Supplemental New Drug Application for Myrbetriq® (mirabegron) Tablets in Pediatric Patients
Read More
U.S.A.
News / Therapeutic Area News
Dec 21, 2020
Astellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
Read More
U.S.A.
News / Corporate
Dec 14, 2020
Astellas and MBC BioLabs Announce Winners of Golden Ticket Competition to Support Biotech Start-ups Accelerate Early Drug Discovery and Innovation
Read More
View All >>
Patients & Caregivers

Learn more about resources designed to meet the needs of patients and caregivers

Read More
Investors

Access financial information, investor relations library, analyst coverage and more

Read More
Contact Us

Call us at (800) 888-7704, M-F, 8AM-7PM CT

Read More

Homepage External Link

Astellas LogoAstellas Changing Tomorrow

Follow us on social media

Facebook icon Linkedin icon Twitter icon

Bottom footer menu

  • SITE MAP
  • PRIVACY POLICY
  • ACCESSIBILITY
  • LEGAL DISCLAIMER
  • CONTACT US
© 2020 Astellas Pharma US, Inc.